

(51) International Patent Classification:
A61K 31/519 (2006.01)(21) International Application Number:
PCT/US2013/070472(22) International Filing Date:
18 November 2013 (18.11.2013)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
61/728,390 20 November 2012 (20.11.2012) US
61/774,087 7 March 2013 (07.03.2013) US(71) Applicant: **GLAXOSMITHKLINE LLC** [US/US]; 5
Crescent Drive, Philadelphia, Pennsylvania 19112 (US).(72) Inventors: **COE, Diane Mary**; c/o GlaxoSmithKline,
Global Patents Department, Gunnels Wood Road, Steven-
age Hertfordshire SG1 2NY (GB). **SMITH, Stephen Al-**
lan; c/o GlaxoSmithKline, Global Patents Department,
Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY
(GB).(74) Agents: **COULTER, Kathryn L.** et al.; c/o GlaxoSmithK-
line, Global Patents Department, Five Moore Drive, P. O.
Box 13398, Research Triangle Park, North Carolina 27709
(US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Compounds of formula (I) and salts thereof: wherein R₁ is n-C4-6alkyl or C1-2alkoxyC1-2alkyl-; R₂ is hydrogen or methyl; each R₃ is hydroxy, halo or n-C1-3alkyl; m is an integer having a value of 2 to 4; n is an integer having a value of 0 to 3; and p is an integer having a value of 0 to 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))